Safety of testosterone therapy in men with prostate cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70:862–874.
   PubMed Web of Science ®Google Scholar
• Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Men’s Health. 2018;12:1807–1823.
   PubMed Web of Science ®Google Scholar
• Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol. 2008;9:445–452.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30:195–200.
   PubMed Web of Science ®Google Scholar
• Grunfeld EA, Halliday A, Martin P, et al. Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms. Cancer Nurs. 2012;35:63–69.
   PubMed Web of Science ®Google Scholar
• Yassin A, Haider A, Haider KS, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care. 2019.
   PubMed Web of Science ®Google Scholar
• Yao QM, Wang B, An XF, et al. Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis. Endocr Connect. 2018;7:220–231.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15:1260–1271.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007–3019.
   PubMed Web of Science ®Google Scholar
• Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J. 2010;31:1494–1501.
   PubMed Web of Science ®Google Scholar
• Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;116:2694–2701.
   PubMed Web of Science ®Google Scholar
• Vigen R, O’Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–1836.
   PubMed Web of Science ®Google Scholar
• Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS One. 2014;9:e85805.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. Aging Male. 2014;17:63–65.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Kacker R. Andrology: testosterone and cardiovascular risk – deciphering the statistics. Nat Rev Urol. 2014;11:131–132.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Traish A, Kacker R. Deaths and cardiovascular events in men receiving testosterone. JAMA. 2014;311:961–962.
   PubMedGoogle Scholar
• Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! J Sex Med. 2014;11:624–629.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Letter to JAMA asking for retraction of misleading article on testosterone therapy; [cited 2019 Aug 5]. Availible from: https://www.androgenstudygroup.org/index.php/initiatives/letter-to-jama-asking-for-retraction-of-misleading-article-on-testosterone-therapy
   Google Scholar
• Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–2058.
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–733.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48:1138–1144.
   PubMed Web of Science ®Google Scholar
• Eisenberg ML, Li S, Herder D, et al. Testosterone therapy and mortality risk. Int J Impot Res. 2015;27:46–48.
   PubMed Web of Science ®Google Scholar
• Shores MM. Testosterone treatment and cardiovascular events in prescription database studies. Asian J Androl. 2018 Mar-Apr;20(2):138–144.
   PubMed Web of Science ®Google Scholar
• Houghton DE, Alsawas M, Barrioneuvo P,et al. Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2018;172:94–103.
   PubMed Web of Science ®Google Scholar
• Saad F, Caliber M, Doros G, et al. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2019 Feb 20:1–12.
   Web of Science ®Google Scholar
• Corona G, Rastrelli G, Guaraldi F, et al. An update on heart disease risk associated with testosterone boosting medications. Expert Opinion on Drug Safety. 2019;18(4):321–332.
   PubMed Web of Science ®Google Scholar
• Tan RS, Cook KR, Reilly WG. Myocardial infarction and stroke risk in young healthy men treated with injectable testosterone. Int J Endocrinol. 2015;2015:970750.
   PubMedGoogle Scholar
• Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–2715.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Morgentaler A, et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc. 2015;90:1038–1045.
   PubMed Web of Science ®Google Scholar
• Etminan M, Skeldon SC, Goldenberg SL, et al. Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study. Pharmacotherapy. 2015;35:72–78.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Scovell J, Mederos M, et al. Association between testosterone supplementation therapy and thrombotic events in elderly men. Urology. 2015;86:283–285.
   PubMedGoogle Scholar
• Haider A, Yassin A, Haider KS, et al. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag. 2016;12:251–261.
   PubMed Web of Science ®Google Scholar
• Anderson JL, May HT, Lappe DL, et al. Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system. Am J Cardiol. 2016;117:794–799.
   PubMed Web of Science ®Google Scholar
• Traish AM, Haider A, Haider KS, et al. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther. 2017;22:414–433.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2009;181:972–979.
   PubMed Web of Science ®Google Scholar
• Gooren LJ, Behre HM. Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. Aging Male. 2012;15:22–27.
   PubMed Web of Science ®Google Scholar
• Millar AC, Elterman DS, Goldenberg L, et al. A survey of Canadian urologists’ opinions and prescribing patterns of testosterone replacement therapy in men on active surveillance for low-risk prostate cancer. Can Urol Assoc J. 2016;10:181–184.
   PubMed Web of Science ®Google Scholar
• Payne H, McMenemin R, Bahl A, et al. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: a survey of UK uro-oncologists’ opinions and practice. Int J Clin Pract. 2019;Sep;73(9):1–6.
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297.
   Google Scholar
• Huggins C, Stevens REJ, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Arch Surg. 1941;43:209–223.
   Google Scholar
• Kava BR. To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer. Curr Urol Rep. 2014;15:422.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer. J Sex Med. 2008;5:1834–1840.
   PubMed Web of Science ®Google Scholar
• Khera M, Crawford D, Morales A, et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014;65:115–123.
   PubMed Web of Science ®Google Scholar
• Atan A, Tuncel A, Yesil S, et al. Serum testosterone level, testosterone replacement treatment, and prostate cancer. Adv Urol. 2013;2013:275945.
   PubMedGoogle Scholar
• Gooren LJ, Behre HM, Saad F, et al. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male. 2007;10:173–181.
   PubMed Web of Science ®Google Scholar
• Anaissie J, DeLay KJ, Wang W, et al. Testosterone deficiency in adults and corresponding treatment patterns across the globe. Transl Androl Urol. 2017;6:183–191.
   PubMed Web of Science ®Google Scholar
• Schroder F, Crawford ED, Axcrona K, et al. Androgen deprivation therapy: past, present and future. BJU Int. 2012;109(Suppl 6):1–12.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–320.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996;276:1904–1906.
   PubMed Web of Science ®Google Scholar
• Tu H, Gu J, Meng QH, et al. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett. 2017;13:1949–1957.
   PubMed Web of Science ®Google Scholar
• Garcia-Cruz E, Piqueras M, Huguet J, et al. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int. 2012;110:E541–6.
   PubMed Web of Science ®Google Scholar
• Li T, Sun X, Chen L. Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function. BMC Cancer. 2019;19:87.
   PubMed Web of Science ®Google Scholar
• Leon P, Seisen T, Cussenot O, et al. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer. Urol Oncol. 2015;33:384.e21–7.
   PubMed Web of Science ®Google Scholar
• Claps M, Petrelli F, Caffo O, et al. Testosterone levels and prostate cancer prognosis: systematic review and meta-analysis. Clin Genitourin Cancer. 2018;16:165–75.e2.
   PubMed Web of Science ®Google Scholar
• Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–183.
   PubMed Web of Science ®Google Scholar
• Monath JR, McCullough DL, Hart LJ, et al. Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology. 1995;46:58–61.
   PubMed Web of Science ®Google Scholar
• Monda JM, Myers RP, Bostwick DG, et al. The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology. 1995;46:62–64.
   PubMed Web of Science ®Google Scholar
• Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118:731–741.
   PubMed Web of Science ®Google Scholar
• Wallis CJ, Lo K, Lee Y, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4:498–506.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern Myth. Eur Urol. 2006;50:935–939.
   PubMed Web of Science ®Google Scholar
• Cooper CS, Perry PJ, Sparks AE, et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998;159:441–443.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:E1172–81.
   Web of Science ®Google Scholar
• Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf). 1994;40:341–349.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Benesh JA, Denes BS, et al. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med. 2014;11:2818–2825.
   PubMed Web of Science ®Google Scholar
• Khera M, Bhattacharya RK, Blick G, et al. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186:1005–1011.
   PubMed Web of Science ®Google Scholar
• Traish AM, Muller RE, Wotiz HH. A new procedure for the quantitation of nuclear and cytoplasmic androgen receptors. J Biol Chem. 1981;256:12028–12033.
   PubMed Web of Science ®Google Scholar
• Traish AM, Williams DF, Hoffman ND, et al. Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. Prog Clin Biol Res. 1988;262:145–160.
   PubMedGoogle Scholar
• Chuu CP, Hiipakka RA, Fukuchi J, et al. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005;65:2082–2084.
   PubMed Web of Science ®Google Scholar
• Song W, Khera M. Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl. 2014;16:864–868.
   PubMed Web of Science ®Google Scholar
• Song W, Soni V, Soni S, et al. Testosterone inhibits the growth of prostate cancer xenografts in nude mice. BMC Cancer. 2017;17:635.
   PubMed Web of Science ®Google Scholar
• Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990;126:1165–1172.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224.
   PubMed Web of Science ®Google Scholar
• Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351–2361.
   PubMed Web of Science ®Google Scholar
• Feneley MR, Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med. 2012;9:2138–2149.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335:1–7.
   PubMed Web of Science ®Google Scholar
• Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–2575.
   PubMed Web of Science ®Google Scholar
• Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49:191–196.
   PubMed Web of Science ®Google Scholar
• Moon DG, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido((R))) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med. 2010;7:2253–2260.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670–2677.
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085–2098.
   PubMed Web of Science ®Google Scholar
• Debruyne FM, Behre HM, Roehrborn CG, et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the registry of hypogonadism in men. BJU Int. 2017;119:216–224.
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–1457.
   PubMed Web of Science ®Google Scholar
• Sonnenschein C, Olea N, Pasanen ME, et al. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res. 1989;49:3474–3481.
   PubMed Web of Science ®Google Scholar
• Hatzoglou A, Kampa M, Kogia C, et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab. 2005;90:893–903.
   PubMed Web of Science ®Google Scholar
• Chuu CP, Kokontis JM, Hiipakka RA, et al. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Cancer Sci. 2011;102:2022–2028.
   PubMed Web of Science ®Google Scholar
• Geck P, Maffini MV, Szelei J, et al.. Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. Proc Natl Acad Sci. 2000;97:10185–10190.
   PubMed Web of Science ®Google Scholar
• Kokontis JM, Lin HP, Jiang SS, et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2. PloS One. 2014;9:e109170.
   PubMed Web of Science ®Google Scholar
• Chuu CP, Kokontis JM, Hiipakka RA, et al. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci. 2011;18:63.
   PubMed Web of Science ®Google Scholar
• Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–536.
   PubMed Web of Science ®Google Scholar
• Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009;103:62–64.
   PubMed Web of Science ®Google Scholar
• Pastuszak AW, Pearlman AM, Godoy G, et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25:24–28.
   PubMed Web of Science ®Google Scholar
• Kacker R, Hult M, San Francisco IF, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016;18:16–20.
   PubMed Web of Science ®Google Scholar
• Bryant C, Hoppe BS, Mendenhall NP, et al. Testosterone replacement therapy in men with prostate cancer after proton therapy. Int J Part Ther. 2014;1:682–691.
   Google Scholar
• Balbontin FG, Moreno SA, Bley E, et al. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014;114:125–130.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Lipshultz LI, Bennett R, et al. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185:1256–1260.
   PubMedGoogle Scholar
• Kardoust Parizi M, Abufaraj M, Fajkovic H, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis. Urol Oncol. 2019 Oct;37(10):637–646.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439.
   PubMed Web of Science ®Google Scholar
• Kaplan AL, Trinh QD, Sun M, et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med. 2014;11:1063–1070.
   PubMed Web of Science ®Google Scholar
• Kaplan AL, Lenis AT, Shah A, et al. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med. 2015;12:374–380.
   PubMed Web of Science ®Google Scholar
• Pastuszak AW, Khanna A, Badhiwala N, et al. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015;194:1271–1276.
   PubMed Web of Science ®Google Scholar
• Kaplan AL, Hu JC, Morgentaler A, et al. Testosterone therapy in men with prostate cancer. Eur Urol. 2016;69:894–903.
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920–922.
   PubMed Web of Science ®Google Scholar
• Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6:1165–1170.
   PubMed Web of Science ®Google Scholar
• Leibowitz RL, Dorff TB, Tucker S, et al. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 2010;105:1397–1401.
   PubMed Web of Science ®Google Scholar
• Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190:639–644.
   PubMed Web of Science ®Google Scholar
• Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536–541.
   PubMed Web of Science ®Google Scholar
• Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304:2373–2380.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Barry JM, Burke W, et al. National institutes of health state-of-the-science conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012;156:591–595.
   PubMed Web of Science ®Google Scholar
• Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–131.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med. 2009;6:574–577.
   PubMed Web of Science ®Google Scholar
• Morales A. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int. 2011;107:1369–1373.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Rahul K, Takeda T, et al. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer. Urol Oncol. 2016;34:530.e9-.e14.
   PubMed Web of Science ®Google Scholar
• San Francisco IF, Werner L, Regan MM, et al. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol. 2011;185:471–476.
   PubMed Web of Science ®Google Scholar
• Ory J, Flannigan R, Lundeen C, et al. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016;196:1082–1089.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Antonarakis ES, Wang H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7:269ra2.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Wang H, Luber B, et al. Bipolar androgen therapy for men with androgen ablation naive prostate cancer: results from the Phase II BATMAN study. Prostate. 2016;76:1218–1226.
   PubMed Web of Science ®Google Scholar
• Teply BA, Wang H, Luber B, et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018;19:76–86.
   PubMed Web of Science ®Google Scholar
• Krakowsky Y, Morgentaler A. Risk of testosterone flare in the era of the saturation model: one more historical Myth. Eur Urol Focus. 2019;5:81–89.
   PubMedGoogle Scholar
• Vis AN, van der Sluis TM, Al-Itejawi HHM, et al. Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact? Urol Oncol. 2015;33:7–15.
   PubMed Web of Science ®Google Scholar